Search

Search results

755 results found

The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt.

Publication: Journal Article

Chiang, George J, Brian R Billmeyer, David Canes, John Stoffel, Alireza Moinzadeh, Christina A Austin, Monika Kosakowski, Kimberly M Rieger-Christ, John A Libertino, and Ian C Summerhayes. 2005. “The Src-Family Kinase Inhibitor PP2 Suppresses the in Vitro Invasive Phenotype of Bladder Carcinoma Cells via Modulation of Akt.”. BJU International 96 (3): 416-22.

Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo.

Publication: Journal Article

Canes, David, George J Chiang, Brian R Billmeyer, Christina A Austin, Monika Kosakowski, Kimberly M Rieger-Christ, John A Libertino, and Ian C Summerhayes. 2005. “Histone Deacetylase Inhibitors Upregulate Plakoglobin Expression in Bladder Carcinoma Cells and Display Antineoplastic Activity in Vitro and in Vivo.”. International Journal of Cancer 113 (5): 841-8.

The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression.

Publication: Journal Article

Yee, Amy S, Eric K Paulson, Michael A McDevitt, Kimberly Rieger-Christ, Ian Summerhayes, Stephen P Berasi, Jiyoung Kim, Chun-Yin Huang, and Xiaowei Zhang. 2004. “The HBP1 Transcriptional Repressor and the P38 MAP Kinase: Unlikely Partners in G1 Regulation and Tumor Suppression.”. Gene 336 (1): 1-13.

BIDMC Glycomics Core Launches SUGA for Rapid N-Glycan Profiling

News: January 05, 2026

Many biologically critical proteins such as viral surface proteins (including SARS-CoV-2 spike), antibodies, and cell-surface receptors are heavily glycosylated, and these sugars can profoundly influence protein function, stability, immune recognition, and drug response. A new Journal of Proteome...

2025 BIDMC Cores Science Day

News: October 27, 2025

Please click here for event details.

Dr. Somnath Bose publishes study identifying priorities of patients who survive an Intensive Care unit stay

News: January 01, 2026

Surviving ICU stay is often just the first step in a long road to recovery for most. The aftermath of critical illness is often challenging for survivors and their caregivers who bear the burden of post-intensive care syndrome (PICS). Unfortunately, there is very little investigation on how...

MicroRNA spatial profiling for assessing drug efficacy in BRCA1-related triple-negative breast tumors

Publication: Journal Article

Mohd, Omar N, Lin Wang, Brian R Sardella, David Jou, Gerburg M Wulf, Frank J Slack, Yujing J Heng, and Patrick S Doyle. 2026. “MicroRNA Spatial Profiling for Assessing Drug Efficacy in BRCA1-Related Triple-Negative Breast Tumors”. BioRxiv, 2026.01.12.698824.

Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.

Publication: Journal Article

Prete, Alessandro, Agnes S Lo, Peter M Sadow, Swati S Bhasin, Zeus A Antonello, Danica M Vodopivec, Soumya Ullas, et al. 2018. “Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.”. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24 (23): 6078-97.

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

Publication: Journal Article

Duquette, Mark, Peter M Sadow, Amjad Husain, Jennifer N Sims, Zeus A Antonello, Andrew H Fischer, Chen Song, et al. 2015. “Metastasis-Associated MCL1 and P16 Copy Number Alterations Dictate Resistance to Vemurafenib in a BRAFV600E Patient-Derived Papillary Thyroid Carcinoma Preclinical Model.”. Oncotarget 6 (40): 42445-67.

Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).

Publication: Journal Article

Husain, Amjad, Nina Hu, Peter M Sadow, and Carmelo Nucera. 2016. “Expression of Angiogenic Switch, Cachexia and Inflammation Factors at the Crossroad in Undifferentiated Thyroid Carcinoma With BRAF(V600E).”. Cancer Letters 380 (2): 577-85.